Study

Study design

Mean Age (years)

Country

Prednisolone dose (mg/day)/duration (months)

Intervention and Number of participants (n)

Co-interventions and Number of participants (n)

Duration of study (months)

Outcomes^a

Denosumab

comparison

Denosumab

comparison

Suzuki [28]

Retrospective

48

Japan

5.1/38.6

-

SC, 60 mg every 6 months (n = 48)

-

Denotas^® chewable (n = 6)

Eldecalcitol (n = 11)

Alfacalcidol (n = 8)

12

125

Iseri [32]

Randomized controlled

study

66.3

Japan

5/83

5/108

SC, 60 mg every 6 months (n = 14)

Alendronate 35 mg/week (n = 14)

Calcitriol (n = 1), Eldecalcitol (n = 10),

Alfacalcidol n = 7)

12

23457

Akashi [27]

-

64.19

Japan

10.59/-

-

(n = 53)

-

-

24

23

Dore [26]

Randomized double-blinded placebo controlled

55.5

USA

5/≥ 3

5/≥ 3

SC, 60 mg (n = 28) or 180 mg (n = 33) every 6 months

Placebo, SC (n = 29)

Biphosphonates

12

12567

Ishiguro [24]

Prospective

73.1

Japan

8.68/41.4

-

SC, 60 mg every 6 months (n = 36)

-

Denotas^® (n = 36)

28

1236

Sawamura [25]

Prospective

50.4

Japan

7.4/208.8

-

SC, 60 mg every 6 months (n = 29)

-

Alfacalcidol (n = 13)

Eldecalcitol (n = 7)

12

23567

Iwamoto [29]

Retrospective

63.4

Japan

5.92/139.2

-

SC, 60 mg every 6 months (n = 66)

-

Vitamin D and calcium (n = 15)

Active vitamin D (n = 51)

12

2567

Saag

[31]

Multicenter

Randomized double-blinded active controlled

63.7

USA

Netherlands

Canada

Argentina

France

14.45/-

13.35/-

SC, 60 mg every 6 months and placebo to risedronate orally once a day for 24 months. (n = 398)

Risedronate oral 5 mg daily and placebo to denosumab by subcutaneous injection every 6 months

(n = 397)

1000 mg calcium

800 IU vitamin D

24

123567

Kadoba [33]

Retrospective

67 (median age)

Japan

≥ 0.8 perkg/-

≥ 0.8 perkg/-

(n = 16)

Bisphosphonates (n = 56)

-

30.5

67

Tanaka [34]

Longitudinal cohort

65

Japan

6.2/-

6.2/-

(n = 60)

Bisphosphonates (n = 150)

-

12

6

Yoshi [30]

-

71.9

Japan

3.49/51.9

5.49/84.7

(n = 21)

Bisphosphonates (n = 24), no drugs administered (n = 48)

-

12

238

Mok [35]

Randomized, open, active controlled

54.7

Hong Kong

4.6/108.2

4.12/94.1

SC, 60 mg every 6 months (n = 21)

Bisphosphonates (n = 21)

Elemental calcium (n = 42)

Calcitriol (n = 42)

12

123567